Tang Capital controls 8.8%, or 8.82 million shares, of Acelyrin, according to a U.S. Securities and Exchange Commission filing. The San Diego-based firm owns 9.6%, or 5.86 million shares ...

The late-stage biopharma said the plan will issue one right for each share of common stock as of the close of business on March 24. The rights will initially trade with its common stock, and will become exercisable only if any person acquires 10% or more of Acelyrin's outstanding common stock.